5Hari PN,Zhang MJ,Roy V,et al, Is the International Staging Sys- tem superior to the Durie-Salrnon staging system? A comparison in multiple myeloma patients undergoing autologous transplant [J]. Leukemia, 2009,23 (8) : 1528-1534. 被引量：1
6Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk strati- fication and response assessment of multiple myeloma[J]. Leuke- mia,2000,23(1) :3-9. 被引量：1
8Kim SJ,Kim K,Kim BS,et al. Clinical features and survival out- comes in patients with multiple myeloma : analysis of web-based data from the Korean Myeloma Registry [ J ]. Acta Haematol, 2009,122 ( 4 ) : 200 -210. 被引量：1
9Kim HJ, Yoon SS, Lee DS, et al. Sequential vincristine, Adriamy-cin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose thera- py with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiplw myeloma:results of a phase 1I trial [ J ]. Ann Hemato1,2012,91 (2) :249-256. 被引量：1
10Facon T, Mary J, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma ( IFM 99-06 ) : a randomised trial [ J ]. Lancet, 2007,370 ( 9594 ) : 1209 -1218. 被引量：1
